Oppenheimer Downgrades Capricor's Target Price

Summary

Oppenheimer has reduced its target price for Capricor Therapeutics (NASDAQ: CAPR) from $43.00 to $22.00 while maintaining an ‘outperform’ rating. Despite the lowered target, this suggests a potential upside of 201.95% from the previous closing price. Opinions from other brokerages vary, with one downgrading to ‘sell’ and others maintaining ‘buy’ ratings with target prices ranging from $30.00 to $77.00. Capricor’s stock is currently trading at $7.29, with a market cap of $332.82 million and a recent negative earnings per share of ($0.53).Market Beat

Impact Analysis

The event is at the company level, focusing on Capricor Therapeutics. Oppenheimer’s reduction in the target price, despite maintaining a positive rating, reflects a reassessment of the company’s valuation, possibly due to recent financial performance or market conditions. The significant potential upside indicates confidence in future prospects but highlights current volatility and risk. Investors may view this as a buying opportunity given the disparity in analyst opinions and potential for high returns, but must also weigh the risks associated with the company’s negative earnings and mixed analyst ratings.Market Beat